title: Local delivery of enoxaparin to decrease restenosis after stenting: results of initial multicenter trial: Polish-American Local Lovenox NIR Assessment study (The POLONIA study).
abstract: BACKGROUND
  Enoxaparin inhibits smooth muscle cell proliferation in experimental models. Intimal hyperplasia has been found to be the principal cause of restenosis after coronary stent implantation. We sought to determine whether the intramural delivery of enoxaparin before stenting of de novo lesions decreases restenosis.
  
  
  RESULTS
  One hundred patients who were undergoing stenting were randomly assigned to either local administration of enoxaparin during predilation with reduced systemic heparinization or stenting with standard, systemic heparinization. All patients were treated with the same type of stent (NIR). The primary study end point was late luminal loss. The secondary end points were major adverse cardiac events, target lesion revascularization, and angiographic restenosis at 6 months. Angiographic follow-up at 6 months was completed in all except 1 patient. Late luminal loss was reduced to 0.76+/-0.42 mm in the local enoxaparin delivery group versus 1. 07+/-0.49 mm in the systemic heparinization group (P:<0.001). Restenosis, using a binary definition, occurred in 10% of patients in the enoxaparin group and in 24% of patients in the systemic heparinization group (P:<0.05). Target lesion revascularization rates occurred in 8% of the enoxaparin group and 22% of the systemic heparinization group (P:<0.05). There were no deaths and no emergent CABGs were performed. The only subacute stent closure and non-Q-wave infarction occurred in a patient assigned to the systemic heparinization group.
  
  
  CONCLUSIONS
  This is the first prospective randomized trial in which the local delivery of a drug, enoxaparin, resulted in significant reduction in late luminal loss and restenosis after stent implantation in de novo coronary lesions.
authors.affiliation: Department of Medicine, Division of Cardiology, University of Texas Health Science Center at San Antonio, TX 78229-7872, USA.
authors.forename: R S
authors.initials: RS
authors.lastname: Kiesz
authors.forename: P
authors.initials: P
authors.lastname: Buszman
authors.forename: J L
authors.initials: JL
authors.lastname: Martin
authors.forename: E
authors.initials: E
authors.lastname: Deutsch
authors.forename: M M
authors.initials: MM
authors.lastname: Rozek
authors.forename: E
authors.initials: E
authors.lastname: Gaszewska
authors.forename: M
authors.initials: M
authors.lastname: Rewicki
authors.forename: P
authors.initials: P
authors.lastname: Seweryniak
authors.forename: M
authors.initials: M
authors.lastname: Kosmider
authors.forename: M
authors.initials: M
authors.lastname: Tendera
mesh_terms: D000925:Anticoagulants / Q000627:therapeutic use; D001241:Aspirin / Q000627:therapeutic use; D004333:Drug Administration Routes; D016503:Drug Delivery Systems; D017984:Enoxaparin / Q000008:administration & dosage*; D005260:Female; D005500:Follow-Up Studies; D006083:Graft Occlusion, Vascular / Q000517:prevention & control*; D006801:Humans; D008297:Male; D008875:Middle Aged; D017202:Myocardial Ischemia / Q000188:drug therapy* / Q000601:surgery*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D011044:Poland; D011446:Prospective Studies; D015607:Stents / Q000009:adverse effects; D013988:Ticlopidine / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000925:Anticoagulants; D017984:Enoxaparin; D010975:Platelet Aggregation Inhibitors; D013988:Ticlopidine; D001241:Aspirin